Galderma to Buy ZO Skin Health for $1.5B
The acquisition is expected to be EPS-neutral in its first year.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
The acquisition is expected to be EPS-neutral in its first year.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.